Cleveland Research Lowers DENTSPLY SIRONA Inc. (XRAY) to Neutral

Cleveland Research lowered shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) from a buy rating to a neutral rating in a research report report published on Thursday morning, MarketBeat Ratings reports.

XRAY has been the topic of a number of other reports. BidaskClub downgraded shares of DENTSPLY SIRONA from a sell rating to a strong sell rating in a research report on Wednesday, August 16th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a hold rating to a sell rating in a research report on Monday, August 14th. Credit Suisse Group restated an outperform rating and set a $75.00 target price (up from $67.00) on shares of DENTSPLY SIRONA in a research report on Thursday, July 13th. UBS AG restated a neutral rating and set a $59.00 target price (down from $62.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Finally, Stifel Nicolaus restated a buy rating and set a $66.00 target price (down from $70.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. DENTSPLY SIRONA has a consensus rating of Hold and a consensus target price of $65.89.

DENTSPLY SIRONA (XRAY) traded down 0.80% during mid-day trading on Thursday, hitting $58.51. 3,205,156 shares of the company were exchanged. The company has a 50 day moving average of $57.21 and a 200 day moving average of $61.25. DENTSPLY SIRONA has a 12-month low of $52.54 and a 12-month high of $65.68. The stock’s market cap is $13.43 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The company had revenue of $992.70 million for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company posted $0.76 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. On average, equities research analysts expect that DENTSPLY SIRONA will post $2.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/08/cleveland-research-lowers-dentsply-sirona-inc-xray-to-neutral.html.

Several large investors have recently made changes to their positions in the stock. Alps Advisors Inc. raised its position in shares of DENTSPLY SIRONA by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock valued at $488,000 after acquiring an additional 20 shares during the period. Wetherby Asset Management Inc. raised its position in shares of DENTSPLY SIRONA by 0.6% in the 2nd quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock valued at $324,000 after acquiring an additional 30 shares during the period. HighTower Advisors LLC raised its position in shares of DENTSPLY SIRONA by 0.6% in the 1st quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock valued at $424,000 after acquiring an additional 39 shares during the period. BRYN MAWR TRUST Co raised its position in shares of DENTSPLY SIRONA by 0.5% in the 2nd quarter. BRYN MAWR TRUST Co now owns 12,064 shares of the medical instruments supplier’s stock valued at $782,000 after acquiring an additional 65 shares during the period. Finally, Atria Investments LLC raised its position in shares

XRAY has been the topic of a number of other reports. BidaskClub downgraded shares of DENTSPLY SIRONA from a sell rating to a strong sell rating in a research report on Wednesday, August 16th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a hold rating to a sell rating in a research report on Monday, August 14th. Credit Suisse Group restated an outperform rating and set a $75.00 target price (up from $67.00) on shares of DENTSPLY SIRONA in a research report on Thursday, July 13th. UBS AG restated a neutral rating and set a $59.00 target price (down from $62.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Finally, Stifel Nicolaus restated a buy rating and set a $66.00 target price (down from $70.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. DENTSPLY SIRONA has a consensus rating of Hold and a consensus target price of $65.89.

DENTSPLY SIRONA (XRAY) traded down 0.80% during mid-day trading on Thursday, hitting $58.51. 3,205,156 shares of the company were exchanged. The company has a 50 day moving average of $57.21 and a 200 day moving average of $61.25. DENTSPLY SIRONA has a 12-month low of $52.54 and a 12-month high of $65.68. The stock’s market cap is $13.43 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The company had revenue of $992.70 million for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company posted $0.76 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. On average, equities research analysts expect that DENTSPLY SIRONA will post $2.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/08/cleveland-research-lowers-dentsply-sirona-inc-xray-to-neutral.html.

Several large investors have recently made changes to their positions in the stock. Alps Advisors Inc. raised its position in shares of DENTSPLY SIRONA by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock valued at $488,000 after acquiring an additional 20 shares during the period. Wetherby Asset Management Inc. raised its position in shares of DENTSPLY SIRONA by 0.6% in the 2nd quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock valued at $324,000 after acquiring an additional 30 shares during the period. HighTower Advisors LLC raised its position in shares of DENTSPLY SIRONA by 0.6% in the 1st quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock valued at $424,000 after acquiring an additional 39 shares during the period. BRYN MAWR TRUST Co raised its position in shares of DENTSPLY SIRONA by 0.5% in the 2nd quarter. BRYN MAWR TRUST Co now owns 12,064 shares of the medical instruments supplier’s stock valued at $782,000 after acquiring an additional 65 shares during the period. Finally, Atria Investments LLC raised its position in shares of DENTSPLY SIRONA by 1.5% in the 2nd quarter. Atria Investments LLC now owns 4,541 shares of the medical instruments supplier’s stock valued at $294,000 after acquiring an additional 68 shares during the period. Institutional investors and hedge funds own 93.87% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply